A Phase II Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Investigating the Safety and Efficacy of Omnitram in Diabetic Neuropathy
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Desmetramadol (Primary)
- Indications Neuropathic pain; Pain
- Focus Therapeutic Use
- Sponsors Syntrix Biosystems
- 17 Sep 2019 Planned End Date changed from 1 Jul 2019 to 1 Mar 2020.
- 17 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Feb 2020.
- 20 Mar 2019 According to the Syntrix Biosystems media release, first patient cohort has been dosed in this study and nearly 20 patients are on study.